axr-159
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 9, 2018 (NCT03598699)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Integrin alpha-4ANTAGONIST
ITGA4 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03598699 | Phase 2 | Jul 9, 2018 | Andover Eye Associates, AxeroVision, Inc., ORA, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Andover Eye Associates | Academic/Hospital | 1 | 0 | 1 | 2018 |
| AxeroVision, Inc. | For profit | 1 | 1 | 1 | 2018 |
| ORA, Inc. | For profit | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1